Predictors of distant metastasis in parotid acinic cell carcinoma

Qigen Fang, Junfu Wu, Wei Du and Xu Zhang

Abstract

Background: Distant metastasis (DM) is a common treatment failure pattern in acinic cell carcinoma (AciCC) of the major salivary glands; therefore, the main goal of this study was to analyse the predictors of DM in parotid AciCC.

Methods: Consecutive patients with surgically treated parotid AciCC who were followed for at least 5 years were retrospectively reviewed. Data regarding age, sex, TNM stage, pathologic characteristics, surgical treatment, and follow-up examinations were collected and analysed. The primary end-point was DM control (DMC); the DMC survival was calculated from the date of surgery to the date of event or the latest follow-up examination and analysed by the Kaplan-Meier method. Independent prognostic factors were evaluated by the Cox proportional hazards method.

Results: A total of 144 patients were included. Positive intraparotid nodes (IPNs) were noted in 34 (31.8%) patients. High-grade transformation was noted in 12 (8.3%) patients. A total of 83 (57.6%) patients underwent neck dissection, and neck node metastasis was proven in 37 (44.6%, 37/83) patients. The 10-year DMC rate was 86%. The Cox model analysis confirmed IPN metastasis (1.854 [1.061–4.144], \( p = 0.011 \)) and high-grade transformation (4.219 [1.948–15.553], \( p < 0.001 \)) as independent predictive factors of the DMC survival.

Conclusion: IPN metastasis and high-grade transformation are independent prognostic factors of the DMC survival.

Keywords: Parotid cancer, Intraparotid node metastasis, Acinic cell carcinoma, High-grade transformation, Distant metastasis

Background

Acinic cell carcinoma (AciCC) of the major salivary glands is relatively uncommon, accounting for nearly 10% of salivary gland malignancies in China [1]. AciCC usually exhibits a relatively non-aggressive course [1–11]. Surgery is the most effective treatment, and adjuvant radiotherapy is suggested when there are adverse pathologic characteristics, including a high tumour stage, neck node metastasis, high-grade transformation, perineural invasion, and lymphovascular invasion [1, 3, 9, 11–14].

Although the reported prognosis and survival data in China are quite favourable, with a 10-year overall survival rate of > 80% [1], a number of patients suffer from disease recurrence. A study from the MD Anderson Cancer Center [9] reported that almost 20% of 155 patients with head and neck AciCC developed distant metastasis (DM), and both Gomez et al. [11] and Zeng et al. [6] reported that the most common treatment failure pattern was DM. However, none of these authors analysed the possible risk factors of DM. Although a number of clinical pathologic variables, including tumour stage, neck lymph node stage, disease stage and disease histology, have been reported to be associated with DM in salivary adenoid cystic carcinoma [15–17], whether there are similar phenomena in parotid AciCC remains unknown. Therefore, the current study aimed to evaluate the predictors of DM in parotid AciCC.

Patients and methods

The Zhengzhou University institutional research committee approved our study, and all participants provided written informed consent for medical research prior to initial treatment. All experiments were performed in accordance with the relevant guidelines and regulations.

* Correspondence: qigenfang@126.com
Department of Head Neck and Thyroid, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan Province, People’s Republic of China

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Consecutive patients surgically treated for primary parotid AciCC from January 2000 to January 2014 were retrospectively evaluated. Eligible patients were > 18 years of age, of either sex, able to provide written informed consent, and had been followed for at least 5 years. Data regarding age, sex, TNM stage, pathologic characteristics, surgical treatment, and follow-up examinations were collected. Intraparotid nodes (IPNs) are nodes located within the parotid tissue [18]. Postoperative radiotherapy is usually advised in our cancer centre when there are high-risk factors, including a high tumour stage, neck node metastasis, high-grade transformation, perineural invasion, lymphovascular invasion and IPN metastasis. After therapy, the patients were required to be examined every 3 months during the first year, every 6 months during the second year, and once per year after the second year by outpatient clinic visits, telephone calls, emails, or WeChat messages.

Systematic examinations were routinely performed for every patient via ultrasound, CT, MRI, and/or PET-CT. The TNM stage was formulated based on the 7th edition of the AJCC classification system.

The primary end-point was DM control (DMC), and the rate of survival with DMC was calculated from the date of surgery to the date of event or the latest follow-up examination. The Kaplan-Meier approach was used to calculate the rate of the DMC survival, and a multivariate Cox proportional hazards model was used to evaluate the independent prognostic factors. All statistical analyses were performed using SPSS 20.0, and p < 0.05 was considered significant.

Results
A total of 144 patients (83 female and 61 male) were included in the analysis, and the mean age at diagnosis was 54.8 (range: 26–76) years. In 13 (9.0%) patients, the tumours were located in the deep lobe of the parotid. Total parotidectomy was performed in 105 (72.9%) patients, superficial parotidectomy was performed in 26 (18.1%) patients, and partial parotidectomy was performed in 13 (9.0%) patients. The pathologic tumour stages were distributed as follows: T1 in 42 (29.2%) cases; T2 in 61 (42.4%) cases; T3 in 27 (18.8%) cases; and T4 in 14 (9.7%) cases. A clear margin was achieved in 140 (97.2%) patients. High-grade transformation was noted in 12 (8.33%) patients. Perineural invasion was noted in 27 (18.8%) patients, and lymphovascular invasion was noted in 21 (14.6%) patients. Information regarding the IPNs was recorded in 107 (74.3%) patients; positive IPNs were noted in 34 (31.8%) patients (Table 1).

A total of 31 (21.5%) patients were classified as cN+ and underwent therapeutic neck dissection (I–V); positive neck nodes were noted in 22 (71.0%, 22/31) patients. A total of 52 (36.1%) patients underwent prophylactic neck dissection (I–III) owing to adverse findings, including a high T stage and nerve invasion; positive neck nodes were noted in 15 (28.9%, 15/52) patients.

The mean follow-up time was 90.7 (range: 16–211) months. Adjuvant radiotherapy was performed in 48 (33.3%) patients, and 8 (5.6%) patients also underwent adjuvant chemotherapy. Recurrence was noted in 41 (28.5%) patients, and 19 (46.3%, 19/41) patients developed DM. When DM was detected, 8 patients had only DM, and 11 patients had simultaneous local or regional recurrence. Lung metastasis occurred in all 19 patients, liver metastasis occurred in 2 patients, vertebral metastasis occurred in 6 patients, sternal metastasis occurred in 2 patients, and rib metastasis occurred in 3 patients. The 5-year overall survival rates for patients with and without DM were 46 and 91%, respectively, the difference was significant (Fig. 1, p < 0.001).

The 10-year DMC rate was 86% (Fig. 2). Univariate analysis showed that age, sex, resection extent, tumour site, margin status, and perineural invasion were not significantly related to DMC (all p > 0.05), while a high tumour

| Characteristics                  | N (%)    |
|----------------------------------|----------|
| Age                              |          |
| < 55                             | 74 (51.4%) |
| ≥ 55                             | 70 (48.6%) |
| Sex                              |          |
| Male                             | 61 (42.3%) |
| Female                           | 83 (57.6%) |
| Tumor stage                      |          |
| T1                               | 42 (29.2%) |
| T2                               | 61 (42.4%) |
| T3                               | 27 (18.8%) |
| T4                               | 14 (9.7%)  |
| Neck node stage a                 |          |
| N0                               | 46 (55.4%) |
| N+                               | 37 (44.6%) |
| Margin                           |          |
| Clear                            | 140 (97.2%) |
| Positive                         | 4 (2.8%)  |
| Tumour site                      |          |
| Superficial                      | 131 (91.0%) |
| Deep                             | 13 (9.0%)  |
| Perineural invasion              | 27 (18.8%) |
| Lymphovascular invasion          | 21 (14.6%) |
| High grade transformation        | 12 (8.3%)  |
| IPN metastasis b                 | 34 (31.8%) |

*a Only patients undergoing neck dissection were analyzed

*b IPN: intraparotid node metastasis, only patients with IPN information were analyzed
**Fig. 1** Overall survival in patients with and without distant metastasis ($p < 0.001$)

**Fig. 2** Survival with distant metastasis control in patients with parotid acinic cell carcinoma
stage ($p = 0.004$), a high disease stage ($p < 0.001$), neck node metastasis ($p = 0.011$), IPN metastasis ($p = 0.048$), no radiotherapy ($p = 0.035$), high-grade transformation ($p = 0.028$), and lymphovascular invasion ($p = 0.009$) were associated with decreased survival with DMC. The Cox model analysis confirmed disease stage ($p < 0.001$, 3.874 [1.843–9.664]), radiotherapy ($p = 0.005$, 0.644 [0.433–0.893]), IPN metastasis ($p = 0.011$, 1.854 [1.061–4.144]), and high-grade transformation ($p < 0.001$, 4.219 [1.948–15.553]) as independent predictive factors of survival with DMC (Table 2).

**Discussion**

DM is relatively uncommon in most head and neck malignancies; the reported incidence of DM in salivary gland cancers ranges from 20 to 50%, varying with different tumour sites and histologic types [14–17, 19]. The finding of the current study are consistent with those of previous reports. Although a few authors have presented the significance of several clinicopathologic characteristics, including cellular differentiation, inflammatory response, tumour invasion pattern, cartilage and/or bone infiltration, perineural infiltration, lymphatic and/or vascular invasion, capsular rupture, lymph node metastasis, and positive surgical margins, in predicting DM in salivary gland carcinomas [14–17, 19–21], no studies in the literature have evaluated the possible risk factors of DM in parotid AciCC. Parotid AciCC is known as a low-grade disease and usually has a good prognosis; therefore, parotid AciCC might have some unique predictors. The current study is the first to analyse the predictors of DM in parotid AciCC.

One of the main findings in the current study is that IPN metastasis apparently decreased the rate of the DMC survival. The value of IPN metastasis in parotid cancer has rarely been discussed. A few authors have reported that IPN metastasis is related to a high tumour stage, neck node metastasis, and adverse pathologic characteristics [13]. Moreover, Lim et al. [22] might have been the first to find that compared to patients without IPN metastasis, patients with a n0 neck with IPN metastasis are more likely to develop locoregional recurrence. In a study published by Klussmann et al. [23], univariate analysis revealed IPN involvement as an additional significant risk factor of tumour recurrence in 55 patients with pN+ tumours. Nisa et al. [24] reported that decreased disease-free survival could be expected in patients with IPN involvement. Recently, we reported that IPN metastasis was associated with poorer local control and that patients with more than two metastatic nodes had the worst prognosis [25]. All of these findings suggest that IPN metastasis is related to a higher risk of recurrence. However, whether IPN metastasis increases the risk of DM remained unknown; we are the first to find that IPN metastasis carries a risk of nearly 2-fold for decreasing survival with DMC. The underlying mechanism might be as follows: first, the N parameter in the TNM classification refers to regional and cervical lymph nodes, and while IPNs appear to play a sentinel role in predicting neck disease, they are not included in any of the neck lymph node groups; second, IPNs include superficial and deep parotid nodes, and unrected positive IPNs might remain after partial or superficial parotidectomy [18].

Another interesting finding was that high-grade transformation predicted poorer DMC survival. High-grade transformation of conventional AciCC is uncommon and includes a variable proportion of a poorly differentiated high-grade component [3–5]. Transformed high-grade AciCC is related to poor clinical outcomes because of the tendency for recurrence and the common occurrence of angiolymphatic and perineural invasion. The clinical course in most cases is fatal, with dissemination followed by tumour-related death [3–5]. Similarly, in the current study, high-grade transformation appeared to have significance in predicting a poorer prognosis.

The role of adjuvant radiotherapy in increasing disease control in parotid cancer remains controversial. Zenga et al. [6] investigated whether there was some survival benefit associated with radiotherapy in parotid AciCC patients with close margins. The authors found that among patients without high-risk factors, those with close margins underwent significantly more radiotherapy, but this difference was not related to improved disease control. Andreoli et al. [8] evaluated the oncologic outcome of 1241 parotid AciCC patients

---

**Table 2** Univariate and cox model analysis of the predictors for distant metastasis control survival

| Variables | Univariate Cox model |
|-----------|----------------------|
|           | Log rank test | HR (95% CI) | p       |
| Age (<55 vs ≥55) | 0.258 | | |
| Sex (Male vs female) | 0.371 | | |
| Tumor stage (T1 + T2 vs T3 + T4) | 0.004 | 2.674 (0.978–7.995) | 0.089 |
| Node stage (N0 vs N+) | 0.011 | 3.612 (0.287–13.611) | 0.483 |
| Disease stage (I + II vs III + IV) | <0.001 | 3.874 (1.843–9.664) | <0.001 |
| Resection extent (TP vs PP + SP)** | 0.482 | | |
| Tumor site (Deep vs superficial) | 0.337 | | |
| Margin (Positive vs negative) | 0.687 | | |
| Perineural invasion | 0.141 | | |
| Lymphovascular invasion | 0.009 | 2.813 (0.846–9.473) | 0.219 |
| High grade transformation | 0.028 | 4.219 (1.948–15.553) | <0.001 |
| IPN metastasis** | 0.048 | 1.854 (1.061–4.144) | 0.011 |
| Radiotherapy | 0.035 | 0.644 (0.433–0.893) | 0.005 |

**TP total parotidectomy, PP partial parotidectomy, SP superficial parotidectomy; IPN intraparotid node metastasis**
and concluded that adjuvant radiotherapy did not seem to provide a significant survival advantage in early-stage or low-grade parotid AciCC. Similar findings have also been reported by Scherl et al. [3] and Neskey et al. [9]. However, Gomez et al. [11] examined overall survival and disease-free survival in patients with varying grades of AciCC that could be treated with adjuvant radiotherapy. Lin et al. [12] reported that radiotherapy could improve the long-term prognosis, especially in patients with advanced-stage disease or positive margins. In the current study, we found that the application of postoperative radiotherapy could improve the DMC survival. One possible explanation is that in our cancer centre, radiotherapy is usually suggested for patients with a high tumour stage, neck node metastasis, and adverse pathologic characteristics, among other features, i.e., those patients at a higher risk of DM.

Disease stage is known to be associated with prognosis in parotid cancer. The results of our previous studies indicated significantly decreased locoregional control and disease-specific survival in advanced-stage parotid cancer [13, 26]. Similar findings have been reported by Rajasekaran et al. [27] and Zhan et al. [28]. However, whether there is a similar trend regarding DM control remained unclear. Recently, Mariano et al. [14] established a relationship between a high disease stage and an increased risk of DM. In the current study, we also found that a high disease stage increased the risk of DM by nearly 4-fold, which confirms the importance of aggressive initial treatment [17].

Other factors, including age, sex, tumour stage, neck node stage, margin status, perineural invasion, and lymphovascular invasion, have been reported to be predictors of the prognosis in parotid cancer [2–11]. In a study consisting of 37 AciCC patients [2], the authors described their independent prognostic variables, including the clinical tumour stage, histopathology-related factors, and the pathologic nodal status. Neskey et al. [9] reported that the male sex, an age greater than 45 years and a tumour size larger than 3 cm were significantly related to decreased survival. However, the main end-point of these studies was survival with locoregional control, disease-specific survival or overall survival. In the current study, these factors were not identified as independent predictive factors of the DMC survival; thus, more studies are needed for clarification.

The limitations of the current study must be acknowledged. First, there is inherent bias in retrospective studies. Second, the sample size was relatively small, possibly reducing the statistical power; therefore, studies with larger sample sizes are needed to verify the results.

Conclusions

In summary, a relatively favourable rate of long-term DMC survival was found in parotid AciCC patients, and IPN metastasis and high-grade transformation significantly decreased the rate of survival with DMC.

Abbreviations

AciCC: Acinic cell carcinoma; DM: Distant metastasis; DMC: Distant metastasis control; IPN: Intraparotid node

Acknowledgements

None declared

Funding

This study was not funded by any outside source.

Availability of data and materials

All data generated or analyzed during this study are included in this published article. And the primary data could be achieved from the corresponding author.

Authors’ contributions

Study design and manuscript writing: W-JF and F-QG. Studies selecting and data analysis: D-W and F-QG. Study quality evaluating: Z-X and F-QG. Manuscript revising: D-W and F-QG. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The Zhengzhou University institutional research committee approved our study, and all participants provided written informed consent for medical research prior to initial treatment, and all experiments were performed in accordance with relevant guidelines and regulations.

Consent for publication

All the material came from our cancer center, and the publish consent have been obtained from all the patients.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 3 January 2019 Accepted: 14 May 2019
Published online: 21 May 2019

References

1. Yu GY, Ma DQ. Diseases of the salivary glands. People’s medical publishing house. 2014. Chinese.
2. Liu Y, Su M, Yang Y, Zhao B, Qin L, Han Z. Prognostic factors associated with decreased survival in patients with acinic cell carcinoma of the parotid gland. J Oral Maxillofac Surg. 2017;75:416–22.
3. Scherl C, Kato MG, Erukul E, Graboyes EM, Nguyen SA, Chi AC, Morgan PF, Day TA. Outcomes and prognostic factors for parotid acinic cell carcinoma: a National Cancer Database study of 2362 cases. Oral Oncol. 2018;82:53–60.
4. Patel NR, Sanghvi S, Khan MN, Husain Q, Baredes S, Eloy JA. Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope. 2014;124:172–8.
5. Skalova A, Sima R, Vanecek T, Muller S, Konaicbaci M, Nemcova J, Elmberger G, Leivo I, Passador-Santos F, Walter J, Rousanova M, Jedlickova K, Curik R, Geierova M, Michal M. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol. 2009;33:1137–45.
6. Zenga J, Parkhi AS, Emerick KS, Lin DT, Faquin WC, Deschler DG. Close margins and adjuvant radiotherapy in acinic cell carcinoma of the parotid gland. JAMA Otolaryngol Head Neck Surg. 2018;144:1011–6.
7. Vander Poorten V, Triantafyllou A, Thompson LD, Bishop J, Hauben E, Hunt J, Skalova A, Stennan G, Takes RP, Gnepp DR, Hellquist H, Weng B, Bell D, Rinaldo A, Ferlito A. Salivary acinic cell carcinoma: reappraisal and update. Eur Arch Otorhinolaryngol. 2016;273:3511–31.
8. Andreoli MT, Andreoli SM, Shlime MG, Davasah AK. Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival? Arch Otolaryngol Head Neck Surg. 2012;138:463–6.
9. Neskey DM, Klein JD, Hicks S, Garden AS, Bell DW, El-Naggar AK, Kies MS, Weber RS, Kuperman ME. Prognostic factors associated with decreased
survival in patients with acinic cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013;139:1195–202.
10. Thompson LD, Aslam MN, Stall JN, Udager AM, Chiosea S, McHugh JB. Clinicopathologic and Immunophenotypic characterization of 25 cases of Acinic cell carcinoma with high-grade transformation. Head Neck Pathol. 2016;10:152–60.
11. Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Gossin RA, Lee NY. Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer. 2009;115:2128–37.
12. Lin WN, Huang HC, Wu CC, Liao CT, Chen IH, Kan CJ, Huang SF. Analysis of acinic cell carcinoma of the parotid gland - 15 years experience. Acta Otolaryngol. 2010;130:1406–10.
13. Fang Q, Liu F, Seng D. Oncologic outcome of parotid mucoepidermoid carcinoma in paediatric patients. Cancer Manag Res. 2019;11:1081–5.
14. Mariano FV, da Silva SD, Chulan TC, de Almeida OP, Kowalski LP. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas. Int J Oral Maxillofac Surg. 2011;40:504–9.
15. Lim WS, Oh J, Roh J, Kim J, Kim S, Choi SH, Nam SY, Kim SY. Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative 18F-FDG PET/CT measurements. Oral Oncol. 2018;77:98–104.
16. Liu Z, Fang Z, Dai T, Zhang C, Sun J, He Y. Higher positive lymph node ratio indicates poorer distant metastasis-free survival in adenoid cystic carcinoma patients with nodal involvement. J Craniomaxillofac Surg. 2015;43:751–7.
17. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997;174:495–8.
18. Niu X, Fang Q, Liu F. Role of intraparotid node metastasis in mucoepidermoid carcinoma of the parotid gland. BMC Cancer. 2019;19:417.
19. Gallo O, Franchi A, Bottai GV, Fini-Storchi I, Tesi G, Boddi V. Risk factors for distant metastases from carcinoma of the parotid gland. Cancer. 1997;80:844–51.
20. Ali S, Bryant R, Palmer FL, DiLorenzo M, Shah JP, Patel SG, Ganly I. Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol. 2015;22:4014–9.
21. Nam SJ, Roh J, Cho K, Choi SH, Nam SY, Kim SY. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23:4376–83.
22. Lim CM, Gilbert MR, Johnson JT, Kim S. Clinical significance of intraparotid lymph node metastasis in primary parotid cancer. Head Neck. 2014;36:1634–7.
23. Lau VH, Aouad R, Farwell DG, Donald PJ, Chen AM. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. Head Neck. 2014;36:1435–9.
24. Nisa L, Salmina C, Dettmer MS, Arnold A, Aebertold DM, Bonier U, Giger R. Implications of intraglandular lymph node metastases in primary carcinomas of the parotid gland. Laryngoscope. 2015;125:2099–106.
25. Feng Y, Liu F, Cheng G, Fang Q, Niu X, He W. Significance of intraparotid node metastasis in predicting local control in primary parotid cancer. Laryngoscope. 2018. https://doi.org/10.1002/lary.27701.
26. Cheng G, Liu F, Niu X, Fang Q. Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients. Cancer Manag Res. 2019;11:2281–6.
27. Rajasekaran K, Stubbs Y, Chen J, Yalamanchi P, Cannady S, Brant J, Newman J. Mucoepidermoid carcinoma of the parotid gland: a National Cancer Database study. Am J Otolaryngol. 2018;39:321–6.
28. Zhan KY, Huang AT, Khaja SF, Bell D, Day TA. Predictors of survival in parotid adenocarcinoma not otherwise specified: a National Cancer Database study of 3155 patients. Head Neck. 2016;38:1208–12.